Convalescent Plasma Transfusion Appears Safe for Patients With COVID-19
The transfusion of human convalescent plasma as a mitigation and treatment option for patients with COVID-19 is associated with a low rate of serious adverse events.
COVID19
Reports of Facial Dermatosis Associated With Prolonged Face Mask Use During COVID-19
The use of PPE in the general population during the COVID-19 pandemic may be associated with the occurrence of facial dermatosis.
Nearly Half of Hispanics, Blacks Scared to Go to Hospital During COVID-19
Hispanics and Blacks are most likely to stay home if experiencing medical emergencies, like a heart attack or stroke, to avoid the risk of contracting COVID-19 at the hospital.
Telemedicine Use Explodes During COVID-19 Pandemic
The emergence of telemedicine has accelerated during the coronavirus pandemic.
The Effect of the COVID-19 Pandemic on Telehealth
Regulations on telehealth services were rapidly deregulated early into the COVID-19 pandemic, but questions remain about quality of care and patient disparities.
Rapid Blood Tests to Aid in COVID-19 Severity, Prognosis
Monitoring hematological and coagulation parameters with rapid blood tests may aid clinicians in the prognosis and severity assessment of COVID-19.
COVID-19 Vaccine Candidate Provides Protection in Animal Challenge Study
Vaccination with mRNA-1273, Moderna’s coronavirus disease 2019 (COVID-19) vaccine candidate, led to robust immune responses and protection against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in nonhuman primates.
Resumption of Athletic Activities in Pediatric Patients Following COVID-19 Infection
The American College of Cardiology has released guidance on pediatric return-to-play for sports participation following COVID-19 infection.
US Cuts Deal With Pfizer, BioNTech for 100 Million COVID-19 Vaccine Doses
The US Department of Health and Human Services and the Department of Defense have agreed to receive 100 million doses of BNT162, a vaccine for SARS-CoV-2, once the manufacturers obtains approval or emergency use authorization (EUA) from the Food and Drug Administration.
Early Data Show Investigational ChAdOx1 nCoV-19 Vaccine Safe, Immunogenic
Interim results from the phase 1/2 COV001 trial evaluating the vaccine candidate ChAdOx1 nCoV-19 (AZD1222) showed that vaccination led to strong immune responses against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in all evaluated participants.
-
Loading...
-
Loading...
Next post in General Dermatology
